Introduction
The need to prospectively identify individuals at ultra high risk (UHR) for psychosis stems from the poor outcomes of psychotic disorders under standard care. 2 The Comprehensive Assessment of At Risk Mental States (CAARMS), was developed in Melbourne 20 years ago 3 to assess and rate the UHR criteria of attenuated psychotic symptoms (APS), brief limited intermittent psychotic symptoms (BLIPS) and trait vulnerability plus decline in psychosocial functioning (Genetic Risk and Deterioration Syndrome, GRD). Since then, the CAARMS has been used to predict incipient risk of transition to psychosis-while it does not predict the onset of incident nonpsychotic disorders 4 -within a relatively short period of time (2 years). 5 The use of the CAARMS is associated with good prognostic accuracy worldwide, 6 at least in help-seeking individuals 7 recruited on suspicion of psychosis risk 8, 9 who have accumulated several risk factors for the development of psychosis. 10 Over the past 2 decades, similar instruments have been developed (eg, the Structured Interview for Prodromal Symptoms, SIPS), 11 each with the goal of facilitating primary indicated interventions in at risk individuals.
Significance of DSM-5 Attenuated Psychosis Syndrome
More recently, a competing diagnostic construct, the DSM-5 Attenuated Psychosis Syndrome (hereafter DSM-5-APS), has been further proposed to identify at risk symptoms. Contrary to popular belief, 13 the DSM-5-APS is not only listed in the research appendix 14 (Section III, starting on page 783) 15 of the DSM-5, but it also appears in the main body of text, in the "Schizophrenia Spectrum and Other Psychotic Disorders" Section (page 122), 15 where it is featured with the official codable diagnosis (298.8) of "Other Specified Schizophrenia Spectrum Disorder and Other Psychotic Disorder." 15 Consequently, 120 years after Kraeplin's claims, 2 competing diagnostic constructs are available to identify individuals at risk for psychosis: the CAARMS (or SIPS) and DSM-5-APS. Competing diagnostic constructs may be a major source of confusion. 16 For example, some authors have started using the DSM-5-APS and CAARMS/SIPS designations interchangeably. 17, 18 However, although both constructs focus on at-risk symptoms, there are profound differences in their operationalization (table 1) .
Initial studies have investigated the basic characteristics of the DSM-5-APS designation in nonclinical samples drawn from schools 23 or the general population, 24 and in clinical samples drawn from outpatients, 25 inpatients, 26 mixed psychiatric clinics 27 or professionals working in general practice. 28 Surprisingly, no study has been designed to directly test the magnitude of diagnostic agreement and disagreement between the DSM-5-APS and the CAARMS within the pool of subjects seeking help at UHR services. Similarly, the prognostic accuracy of the DSM-5-APS designation for the prediction of psychosis is completely unknown.
Here, we present the first study directly investigating the diagnostic and prognostic significance of the DSM-5-APS in help-seeking individuals referred to UHR services and undergoing an assessment on suspicion of psychosis risk. Our first aim was to quantify the diagnostic agreement and disagreement between the DSM-5-APS and the CAARMS in UHR services. Second, we aimed to estimate the prognostic accuracy of the DSM-5-APS compared to the CAARMS standard and assess its potential clinical usefulness in UHR services. Third, we tested the impact of different DSM-5-APS criteria revisions. 20 were included. Possible outcomes of the CAARMS 12/2006 assessment are: at risk for psychosis (UHR+), not at risk for psychosis (UHR−) or already psychotic (Psychosis). Details of the OASIS UHR service have been previously described. 29 The CAARMS 12/2006 is the gold standard UHR assessment instrument at the OASIS. The procedure for staff training, inter-rater reliability measures and the specific types of indicated interventions adopted at OASIS have been detailed in separate manuscripts. 30, 31 For the purpose of the current study, 2 psychiatrists underwent an initial 2-hour debriefing on the use of the DSM-5-APS and, under the supervision of the OASIS consultant (who had more than 10 years of experience in the assessment of UHR individuals), were required to additionally score (yes/no) the 6 DSM-5-APS inclusion criteria (A to F, see table 1 for details) during the face-to-face CAARMS 12/2006 assessment. Importantly, the study sample was designed to reflect at-risk populations as they are encountered in day-to-day practice in UHR services. Avoiding the use of external and non-help-seeking healthy control groups, who do not reflect the clinical composition of people actually screened in UHR services, is essential to assess the real-world diagnostic and prognostic significance of DSM-5-APS in this population. 33 We estimated percent overall agreement, kappa (with its 95% CI) and the Prevalence And Bias Adjusted Kappa (PABAK), 34 which adjusts the kappa for differences in prevalence and bias 35 (see supplementary eMethods 1). Since the null hypothesis with kappa is of disagreement, we measured contingency table symmetry with Bowker's test 36 and marginal homogeneity with the exact Stuart-Maxwell test 37, 38 (these tests are based on a null hypothesis of agreement). Finally, to better elucidate the impact of each specific cell on the overall results, we reported the adjusted residuals and Fisher's exact test and conducted complementary analyses after excluding the BLIPS and GRD cases.
Methods

Sample
Longitudinal Analysis (Prognosis).
We used Cox proportional hazards complete-case analyses to evaluate the effects of the DSM-5-APS designation (DSM-5-APS+ or DSM-5-APS−) on the development of psychotic disorders and time to development of psychosis, after checking the proportional hazards assumption, 39 among those who were not already psychotic at baseline. We also plotted the overall cumulative risk of psychosis onset in individuals assessed for DSM-5-APS with the Kaplan-Meier failure function (1 − survival) 40 and Greenwood 95% CIs. 41 Kaplan-Meier point estimates were also reported, truncated when at least 10 subjects were still at risk. Prognostic accuracy of the DSM-5-APS was further determined with the C statistic. In a first step, we estimated and plotted the time-dependent Receiver Operating Characteristic (ROC) curve and area under time-dependent ROC curve (AUC) for the DSM-5-APS designation at different timepoints, together with 95% confidence bands of AUCs (values of 0.9-1.0 are considered outstanding, 0.8-0.9 excellent, and 0.7-0.8 acceptable 42 ). In a second step, we tested and plotted potential AUCs differences of the 2 competing designations (DSM-5-APS vs CAARMS 12/2006), measured on the same individuals. Time-dependent Sensitivity (Se), Specificity (Sp), Positive Predictive Values (PPV) and Negative Predictive Values (NPV) were additionally computed. Finally, we reported the pretest risk for psychosis along with the positive (LR+) and negative likelihood ratios (LR−) (for details see 43 ) for the DSM-5-APS assessment.
Since these measures do not tell us whether the DSM-5-APS designation would do more good than harm if used in clinical practice, 44 we additionally performed net benefit analyses (for conceptual and methodological details see 44 ). Such an approach includes an "exchange rate," a clinical judgment of the relative value of benefits (such as preventing psychosis in help-seeking individuals) and harms (such as unnecessary treatment) associated with the DSM-5-APS designation. We used 7.69% as an approximate exchange rate as previously validated 45 (see supplementary eMethods 2). However, as the answers to these kinds of questions and the exchange rates are subjective, we additionally plotted the net benefits for a range of reasonable exchange rates in a decision curve analysis, as recommended. 44 Theoretical Impact of DSM-5-APS Revisions. In pilot analyses we tested the theoretical impact of specific revisions of the DSM-5-APS criteria on: diagnostic agreement with the CAARMS 12/2006 (proportion of observed and expected agreement, kappa and P), diagnostic disagreement with the CAARMS 12/2006 (StuartMaxwell test 37, 38 and P), prognostic measures (2-years Se, Sp, PPV, NPV, computed as indicated above) and prognostic performance of the revised model (Harrell's C, which is similar to the AUC 46 ). All analyses were conducted in Stata 13 (STATA Corp.) or R version 3.3.0; statistical tests were 2-sided and statistical significance was defined as P values of less than .05.
Results
Sample Characteristics
The sample consisted of 203 consecutive help-seeking individuals accessing the OASIS UHR service during the recruitment period. The majority were low-functioning (average SOFAS = 53), Black (43%) and male (65%), with an average age of 25 years (range = 16-37 years) (for details see table 2).
Diagnostic Significance: DSM-5-APS vs CAARMS 12/2006
Sociodemographic Characteristics Associated With DSM-5-APS Designation. Upon assessment, 51 individuals were deemed DSM-5-APS+, 91 were DSM-5-APS− and 61 were already psychotic (according to criterion F of the DSM-5-APS). There were no functional, age or sex differences between the 3 groups. Psychotic individuals were more likely to be of black ethnicity. There were also significant between-group differences in symptom severity as measured by the CAARMS 12/2006 subscales, with more severe scores in the psychotic group but no significant symptomatic differences between the DSM-5-APS+ and DSM-5-APS− groups.
Diagnostic Significance. The percent overall agreement between the DSM-5 (DSM-5-APS+, DSM-5-APS−, Psychosis) and the CAARMS 12/2006 (UHR+, UHR−, Psychosis) was 72.91% (expected agreement by chance 34.33%). The kappa was 0.587 (Z = 12.80, P < .001, 95% CI 0.497-0.677) and the PABAK was 0.594 (95% CI 0.529, 0.658), indicating significant agreement of moderate magnitude. However, the tests for table symmetry (X 2 = 55, P < .001) and marginal homogeneity (X 2 = 55, P < .001) were both highly significant, indicating concurrent substantial disagreement between the 2 outcomes. The largest contribution to the symmetry was the fact that 27/105 UHR+ individuals were psychotic on the DSM-5-APS assessment, while there were no psychotic individuals according to the figure 1 . The point estimates for the risk of psychosis in the DSM-5-APS+ group were 15.69% (95% CI 8.17%-28.93%) at 6 months, 17.69% (95% CI 9.62%-31.25%) at 12 months, 20.99% (95% CI 14.80%-49.50%) at 18 months, and 28.17% (95% CI 14.80%-49.50%) at 21 months (for longer follow-ups there were too few individuals still at risk). 
Significance of DSM-5 Attenuated Psychosis Syndrome
The point estimates for the risk of psychosis in the DSM-5-APS− group were 3.30% (95% CI 1.08%-9.87%) at 6 months, 4.62% (95% CI 1.75%-11.90%) at 12 months, Among these 142 individuals there were no significant differences in the ability to predict psychosis between the DSM-5-APS and the CAARMS 12/2006 (test of AUCs differences/non-inferiority: P > .05 at all timepoints), as also shown in the bottom section of figure 2.
Net Benefit Analysis. At the reference threshold for recommending indicated interventions to prevent psychosis (7.69%), treating on the basis of the DSM-5-APS outcome was associated with a small but significant net benefit of 0.027, compared with treat all. The net benefit increased from this probability threshold (risk of psychosis) onwards, up to 35% risk by 2 years. The decision curve (figure 3) confirmed that compared to treating none, treating with indicated interventions on the basis of the DSM-5-APS assessment is associated with net benefits for a range of probability thresholds up to 35% risk by 2 years. For example, the net benefit of 0.099 at a threshold probability of 15% (figure 3), indicates that compared to treating none, treating on the basis of the DSM-5-APS assessment is equivalent to a strategy that treats approximately 10 patients at risk for psychosis per 100 patients, without conducting any unnecessary treatment.
Theoretical Impact of DSM-5-APS Revisions
The overall diagnostic agreement between the DSM-5-APS and the CAARMS 12/2006 and the kappa were the highest, and the disagreement the lowest (albeit still significant), when the criterion B was redefined to include cases with psychotic symptoms lasting up to 1 month and criterion E was conjointly removed (table 4) . The highest Se and NPV were achieved when all criteria B, C, D, and E were removed (but Sp was the lowest). None of the revisions tested showed superior Sp and PPV, compared to the current specifications. Prognostic performance improved when criterion E was removed and was the highest when the criterion C was removed.
Discussion
In 203 consecutive help-seeking individuals accessing UHR services on suspicion of psychosis risk, the agreement between the DSM-5-APS and the CAARMS 12/2006 was significant but only moderate in magnitude (kappa 0.59). Disagreement mostly involved UHR+ individuals under the CAARMS 12/2006, as half of them (one-third of APS cases and all of BLIPS or GRD cases) retained a different designation under the DSM-5-APS. Across 142 nonpsychotic cases followed up for a mean of 1.5 years, those meeting the DSM-5-APS criteria had a 5-fold probability (HR 5.379) of developing a psychotic disorder compared to those not meeting these criteria, with a 21-month cumulative risk of psychosis of 28% and 6%, respectively. The AUC of the DSM-5-APS was acceptable (0.76 at 24 months), with high NPV and modest PPV, and comparable to the AUC of the CAARMS 12/2006 at any timepoint. Decision curve analysis suggested that in nonpsychotic (and non-BLIPS) individuals, the DSM-5-APS designation may be clinically useful within a 7%-35% range of threshold probability (at 2-years). Removal of criterion E or C of the DSM-5-APS may improve its prognostic performance, transdiagnostic value and clinical implementation. This is the first study to address the diagnostic significance of the DSM-5-APS in clinical services for UHR individuals, using the CAARMS 12/2006 as gold standard reference. Our prospective cohort design that included all consecutive individuals seeking help at UHR services and undergoing an assessment on suspicion of psychosis risk allowed estimation of the real-world diagnostic and prognostic significance of the DSM-5-APS in these populations. The sociodemographic characteristics of the current sample and its substantial pretest psychosis risk enrichment (16% at 2 years) are key characteristics of selected populations seeking help at UHR services worldwide. 8, 43, 48 In this clinical context, we found a significant diagnostic agreement ( 17, 18 is not psychometrically sound (but see below re: prognostic non-inferiority). These discrepancies may be of clinical relevance, as the DSM-5-APS is considered a disorder per se, and therefore it is a broad marker for identifying individuals who merit active care to address a variety of symptoms, independent from their longitudinal risk of developing psychosis. 50 This is also the first prospective study to test the actual prognostic significance of the DSM-5-APS designation for psychosis onset in the pool of individuals who were not DSM-5-APS psychotic at baseline, excluding also all BLIPS individuals. BLIPS cases are problematic as they have a distinctive diagnostic and prognostic profile as compared to the APS and GRD subgroups, as extensively demonstrated by our team. 4, 33, 47, 51, 52 We have clearly shown that, over an average follow-up of 1.5 years, DSM-5-APS+ individuals were 5 times more at risk of developing psychosis (HR 5.379), than the DSM-5-APS− individuals. These findings indicate that DSM-5-APS, if used in nonpsychotic patients accessing UHR services, could effectively predict conversion to psychosis. Its ability to rule in psychosis appeared slightly better than that reported for the UHR psychometric instruments. The meta-analytical risk of psychosis of the CAARMS/ SIPS-defined APS group (24-month mean 19%, 95% CI 15%-23%) 33 and the LR+ of the UHR instruments (1.82 at 38 months) 6 seem lower than those reported here for the DSM-5-APS (21-month average risk of psychosis 28.17% and LR+ 2.262). Conversely, the DSM-5-APS appeared slightly less accurate in predicting the absence of psychosis than the psychometric UHR assessment. The meta-analytical risk of psychosis of the CAARMS/ SIPS-defined APS group (24-month mean 1%, 95% CI 0%-3%) 33 and the LR− of the UHR instruments (0.09 at 38 months) 6 seem lower (thus better for excluding psychosis), compared to the DSM-5-APS (21-month average risk of psychosis 6.49%, LR− 0.428). As these differences were counterbalanced, the overall prognostic accuracy of the DSM-5-APS was non-inferior and almost comparable with the CAARMS 12/2006 at any timepoint. On a conceptual side, this finding may appear surprising, given the only moderate diagnostic agreement (kappa) between the 2 instruments. Of interest, prognostic accuracy is also comparable across the CAARMS and the SIPS, 6 despite their substantial diagnostic differences. 31 These observations corroborate the notion that the actual prognostic accuracy of all of these instruments is mostly determined by their pre-test risk enrichment, as our group has extensively shown. 8, 9, 43, 48, 53 Since we found a 16% 2-year pretest risk of psychosis in this help-seeking sample, it is likely that in general non-help seeking populations the DSM-5-APS is associated with substantially lower transition risks. Consequently, most of the findings reported here are not generalizable outside help-seeking samples accessing UHR services.
On a pragmatic side, the finding of non-inferiority of DSM-5-APS for the prediction of psychosis in UHR services, compared to standard psychometric interviews, may have some practical clinical relevance, although further replication studies are required. For example, we qualitatively estimated that a DSM-5-APS assessment is relatively quicker to administer in UHR services, requiring on average 23 minutes, compared with 120 minutes for the CAARMS 12/2006 29 (but see the eLimitations) and recent studies show that the label DSM-5-APS is equally accepted compared to the standard "UHR" or "At Risk Mental State." 54 Our study was also the first to directly investigate the potential clinical usefulness of the DSM-5-APS designation for clinical practice in UHR services. We used net benefit and decision curve analysis approaches-that were originally developed in cancer research-to investigate the clinical usefulness of different strategies for offering indicated interventions to UHR patients, taking into consideration both harms and benefits. We found that in non-BLIPS cases, indicated interventions selected on the basis of the DSM-5-APS outcomes were associated with significant net benefits for a range of psychosis risk (at 2-years), spanning from 7% to 35%. Such a range is clinically meaningful for UHR services since it is unlikely an UHR individual would need a clinical assessment to receive indicated interventions when his/her 2-year risk of psychosis is lower or greater than this range. These findings may be of particular relevance for the continued evaluation of the DSM-5-APS's clinical validity and for its appropriateness for inclusion in the next update of DSM-5.1.
12
We also tested in pilot analyses the first theoretical diagnostic and prognostic impact of some potential revisions of the DSM-5-APS. None of them had a dramatic effect in improving the prognostic performance, presumably in light of the fact that the observed risk in these samples is mostly accounted at pre-test level (ie, 16% risk at 2-years), through the recruitment strategies adopted. However, our analyses suggested that removing either criterion E or C may be associated with an improved prognostic performance. The removal of criterion E, which poses substantial differential diagnostic challenges to clinicians, would additionally facilitate the transdiagnostic potential of the DSM-5-APS and better fill the current implementation gap for the identification of at risk individuals (only 5% of at risk individuals in secondary mental health care are currently detected by UHR services). 45 For example, since the UHR criteria have been successfully applied to individuals affected with 22q11 deletion syndrome 55 or may be used in high potency cannabis users 6 a revision of the DSM-5-APS should allow inclusion of these samples. 56 However, because of the limited sample size, these analyses should be considered cautiously. Future studies may leverage on our methodological approach and validate these findings. Limitations of the study are outlined in the supplementary eLimitations.
Conclusions
In help-seeking individuals accessing UHR services, the DSM-5-APS and the CAARMS 12/2006 definitions of attenuated psychosis symptoms are diagnostically different, but prognostically comparable. The DSM-5-APS designation offers some promising clinical usefulness for the prevention of psychosis that may be improved by future revisions.
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